Effects of the number of amino acid residues in the signal segment upstream or downstream of the NS2B-3 cleavage site on production and secretion of prM/M-E virus-like particles of West Nile virus

Microbes and Infection

Volumn 11, Issue 13, 2009, Pages 1019-1028

  Takahashi, Hidehiro ^a   Ohtaki, Naohiro ^a   Maeda Sato, Masae ^a   Tanaka, Michiko ^a   Tanaka, Keiko ^a   Sawa, Hirofumi ^b   Ishikawa, Toyokazu ^c   Takamizawa, Akihisa ^c   Takasaki, Tomohiko ^a   Hasegawa, Hideki ^a   Sata, Tetsutaro ^a   Hall, William W ^d   Kurata, Takeshi ^a   Kojima, Asato ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

M PROTEIN; MUTANT PROTEIN; NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 2B; PRECURSOR M PROTEIN; SIGNAL PEPTIDE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; WEST NILE VACCINE;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG DOSE COMPARISON; EXPRESSION VECTOR; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN SECRETION; VIRUS LIKE AGENT; WEST NILE FLAVIVIRUS;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; GLYCOSYLATION; HUMANS; MICE; MUTAGENESIS, INSERTIONAL; PROTEIN SORTING SIGNALS; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, PROTEIN; VERO CELLS; VIRAL ENVELOPE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS; VIRION; WEST NILE VIRUS;

MUS; WEST NILE VIRUS;

EID: 70349780374     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2009.07.009     Document Type: Article

References (30)

1. Mukhopadhyay S., Kuhn R.J., and Rossmann M.G. A structural perspective of the flavivirus life cycle, Nat. Rev. Microbiol. 3 (2005) 13-22
2. Elshuber S., Allison S.L., Heinz F.X., and Mandl C.W. Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus. J. Gen. Virol 84 (2003) 183-191
3. Amberg S.M., Nestorowicz A., McCourt D.W., and Rice C.M. NS2B-3 proteinase-mediated processing in the yellow fever virus structural region: in vitro and in vivo studies. J. Virol 68 (1994) 3794-3802
4. Lobigs M. Flavivirus premembrane protein cleavage and spike heterodimer secretion require the function of the viral proteinase NS3. Proc. Natl. Acad. Sci. USA 90 (1993) 6218-6222
5. Lobigs M., and Lee E. Inefficient signalase cleavage promotes efficient nucleocapsid incorporation into budding flavivirus membranes. J. Virol 78 (2004) 178-186
6. Amberg S.M., and Rice C.M. Mutagenesis of the NS2B-NS3-mediated cleavage site in the flavivirus capsid protein demonstrates a requirement for coordinated processing. J. Virol 73 (1999) 8083-8094
7. Huang C.Y., Silengo S.J., Whiteman M.C., and Kinney R.M. Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus. J. Virol 79 (2005) 7300-7310
8. Allison S.L., Stiasny K., Stadler K., Mandl C.W., and Heinz F.X. Mapping of functional elements in the stem-anchor region of tick-borne encephalitis virus envelope protein E. J. Virol 73 (1999) 5605-5612
9. Konishi E., and Mason P.W. Proper maturation of the Japanese encephalitis virus envelope glycoprotein requires cosynthesis with the premembrane protein. J. Virol 67 (1993) 1672-1675
10. Lorenz I.C., Allison S.L., Heinz F.X., and Helenius A. Folding and dimerization of tick-borne encephalitis virus envelope proteins prM and E in the endoplasmic reticulum. J. Virol 76 (2002) 5480-5491
11. Ferlenghi I., Clarke M., Ruttan T., Allison S.L., Schalich J., Heinz F.X., Harrison S.C., Rey F.A., and Fuller S.D. Molecular organization of a recombinant subviral particle from tick-borne encephalitis virus. Mol. Cell 7 (2001) 593-602
12. Roehrig J.T., Staudinger L.A., Hunt A.R., Mathews J.H., and Blair C.D. Antibody prophylaxis and therapy for flavivirus encephalitis infections, Ann. N.Y. Acad. Sci 951 (2001) 286-297
13. Karaca K., Bowen R., Austgen L.E., Teehee M., Siger L., Grosenbaugh D., Loosemore L., Audonnet J.C., Nordgren R., and Minke J.M. Recombinant canarypox vectored West Nile virus (WNV) vaccine protects dogs and cats against a mosquito WNV challenge. Vaccine 23 (2005) 3808-3813
14. Martin J.E., Pierson T.C., Hubka S., Rucker S., Gordon I.J., Enama M.E., Andrews C.A., Xu Q., Davis B.S., Nason M., Fay M., Koup R.A., Roederer M., Bailer R.T., Gomez P.L., Mascola J.R., Chang G.J., Nabel G.J., and Graham B.S. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J. Infect. Dis 196 (2007) 1732-1740
15. Ishikawa T., Takasaki T., Kurane I., Nukuzuma S., Kondo T., and Konishi E. Co-immunization with West Nile DNA and inactivated vaccines provides synergistic increases in their immunogenicities in mice. Microbes Infect 9 (2007) 1089-1095
16. Kojima A., Yasuda A., Asanuma H., Ishikawa T., Takamizawa A., Yasui K., and Kurata T. Stable high-producer cell clone expressing virus-like particles of the Japanese encephalitis virus e protein for a second-generation subunit vaccine. J. Virol 77 (2003) 8745-8755
17. Fonseca B.A., Pincus S., Shope R.E., Paoletti E., and Mason P.W. Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice. Vaccine 12 (1994) 279-285
18. Konishi E., Yamaoka M., Kurane I., and Mason P.W. A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice. Vaccine 18 (2000) 1133-1139
19. Chang G.J., Hunt A.R., and Davis B. A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice. J. Virol 74 (2000) 4244-4252
20. Konishi E., Yamaoka M., Khin Sane W., Kurane I., and Mason P.W. Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes. J. Virol 72 (1998) 4925-4930
21. Pincus S., Mason P.W., Konishi E., Fonseca B.A., Shope R.E., Rice C.M., and Paoletti E. Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology 187 (1992) 290-297
22. Solomon T. Flavivirus encephalitis, N. Engl. J. Med 351 (2004) 370-378
23. Marfin A.A., and Gubler D.J. West Nile encephalitis: an emerging disease in the United States. Clin. Infect. Dis 33 (2001) 1713-1719
24. Shirato K., Miyoshi H., Goto A., Ako Y., Ueki T., Kariwa H., and Takashima I. Viral envelope protein glycosylation is a molecular determinant of the neuroinvasiveness of the New York strain of West Nile virus. J. Gen. Virol 85 (2004) 3637-3645
25. Niwa H., Yamamura K., and Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108 (1991) 193-199
26. Kimura-Kuroda J., and Yasui K. A focus assay method for Japanese encephalitis virus using complement and anti-virus serum, Microbiol. Immunol 29 (1985) 55-63
27. Srivastava A.K., Putnak J.R., Lee S.H., Hong S.P., Moon S.B., Barvir D.A., Zhao B., Olson R.A., Kim S.O., Yoo W.D., Towle A.C., Vaughn D.W., Innis B.L., and Eckels K.H. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine 19 (2001) 4557-4565
28. Mutoh E., Ishikawa T., Takamizawa A., Kurata T., Sata T., and Kojima A. Japanese encephalitis subunit vaccine composed of virus-like envelope antigen particles purified from serum-free medium of a high-producer J12#26 cell clone. Vaccine 22 (2004) 2599-2608
29. Monath T.P., Liu J., Kanesa-Thasan N., Myers G.A., Nichols R., Deary A., McCarthy K., Johnson C., Ermak T., Shin S., Arroyo J., Guirakhoo F., Kennedy J.S., Ennis F.A., Green S., and Bedford P. A live, attenuated recombinant West Nile virus vaccine. Proc. Natl. Acad. Sci. USA 103 (2006) 6694-6699
30. McGee C.E., Tsetsarkin K., Vanlandingham D.L., McElroy K.L., Lang J., Guy B., Decelle T., and Higgs S. Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes. J. Infect. Dis 197 (2008) 686-692